Through complementary experiments involving human samples and mouse tumor models, two groups showed that loss of CD226 induces hypo-responsiveness in CD8+ T cells, and limits both TCR signaling and responsiveness to anti-PD-1 mAbs (28, 29). This evidence concerns the gene CD226 and neoplasm.